Azienda Sanitaria Territoriale Di Pesaro E Urbino
- Address
- lock Available on a paid plan
Azienda Sanitaria Territoriale Di Pesaro E Urbino - Comprehensive Oncology Research Center
The Azienda Sanitaria Territoriale Di Pesaro E Urbino is a leading healthcare institution specializing in advanced oncology research with a particular emphasis on precision medicine and targeted therapies. The center demonstrates exceptional expertise in molecular biomarker-driven clinical trials, particularly in KRAS G12C mutations, HER2-targeted therapies, and immunotherapy combinations across multiple cancer types.
- Non-Small Cell Lung Cancer (NSCLC) with focus on KRAS G12C mutations, HER2 overexpression, and PD-L1 targeted immunotherapy regimens
- Breast Cancer research including triple-negative breast cancer, endocrine-responsive tumors, and adjuvant therapy optimization
- Gastrointestinal malignancies encompassing pancreatic cancer, gastric/gastroesophageal cancer, and metastatic colorectal cancer with liquid biopsy guidance
- Hematologic malignancies including Acute Myeloid Leukemia (AML) with IDH mutations, myelodysplastic syndrome (MDS), and allogeneic hematopoietic cell transplantation
The center is actively engaged in cutting-edge Phase 2 and Phase 3 clinical trials evaluating novel therapeutic strategies, including liquid biopsy-guided treatment selection, switch maintenance therapy, and combination approaches with immune checkpoint inhibitors and targeted agents. Their research portfolio also extends to small cell lung cancer and ulcerative colitis, demonstrating a comprehensive commitment to advancing precision oncology and personalized medicine approaches across diverse therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 66 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 63 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
- 1Fondazione GONO G.I.3active
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondazione GONO G.I.3trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Territoriale Di Pesaro E Urbino
lock Showing 1 of 31 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer | Gilead Sciences Inc. | Phase II | Not Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 66 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 10 | Unknown | 2023-03-16 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.